Posted by Michael Wonder on 13 Jan 2017
Heron announces submission of Cinvanti NDA for the prevention of chemotherapy-induced nausea and vomiting
12 January 2017 - If approved by the U.S. FDA, Cinvanti will strengthen Heron’s chemotherapy-induced nausea and vomiting franchise by adding second, complementary therapeutic agent.
Heron Therapeutics today announced submission of the new drug application for Cinvanti (HTX-019), the first polysorbate 80-free, intravenous formulation of aprepitant for the prevention of chemotherapy-induced nausea and vomiting (CINV) to the U.S. FDA.
Aprepitant belongs to a class of agents known as NK1 receptor antagonists, which are often used in combination with 5-HT3 receptor antagonists for the prevention of CINV.
